Temozolomide (TMZ) stands as the primary chemotherapy choice for glioblastoma multiforme (GBM), yet resistance frequently emerges in patients, leading to tumor recurrence and worsened prognoses. A recent study reported upregulation of glutamine and glutamate transport and metabolism in TMZresistant GBM in silico, particularly highlighting the upregulation of Gene X. Given the reported glutamine…